Furthermore, survival analysis showed that patients with high Lnc-Myd88 expression in HCC had significantly worse prognosis than those with low Lnc-Myd88 expression, with a lower overall survival rate and shorter non-recurrence period (Figure 1f). This evidence concerns the gene MYD88 and hepatocellular carcinoma.